Synlogic (SYBX) Competitors $1.16 +0.02 (+1.75%) As of 03:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SYBX vs. IMRX, PDSB, SKYE, GANX, ICCC, CUE, VNRX, OTLK, AVTX, and CYCCShould you be buying Synlogic stock or one of its competitors? The main competitors of Synlogic include Immuneering (IMRX), PDS Biotechnology (PDSB), Skye Bioscience (SKYE), Gain Therapeutics (GANX), ImmuCell (ICCC), Cue Biopharma (CUE), VolitionRx (VNRX), Outlook Therapeutics (OTLK), Avalo Therapeutics (AVTX), and Cyclacel Pharmaceuticals (CYCC). These companies are all part of the "pharmaceutical products" industry. Synlogic vs. Immuneering PDS Biotechnology Skye Bioscience Gain Therapeutics ImmuCell Cue Biopharma VolitionRx Outlook Therapeutics Avalo Therapeutics Cyclacel Pharmaceuticals Immuneering (NASDAQ:IMRX) and Synlogic (NASDAQ:SYBX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, community ranking, valuation, profitability, earnings, institutional ownership, dividends and media sentiment. Does the MarketBeat Community favor IMRX or SYBX? Synlogic received 295 more outperform votes than Immuneering when rated by MarketBeat users. Likewise, 69.54% of users gave Synlogic an outperform vote while only 69.23% of users gave Immuneering an outperform vote. CompanyUnderperformOutperformImmuneeringOutperform Votes3669.23% Underperform Votes1630.77% SynlogicOutperform Votes33169.54% Underperform Votes14530.46% Which has more risk & volatility, IMRX or SYBX? Immuneering has a beta of -0.25, indicating that its stock price is 125% less volatile than the S&P 500. Comparatively, Synlogic has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500. Do analysts rate IMRX or SYBX? Immuneering presently has a consensus target price of $12.50, suggesting a potential upside of 868.99%. Given Immuneering's stronger consensus rating and higher probable upside, analysts plainly believe Immuneering is more favorable than Synlogic.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immuneering 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33Synlogic 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media refer more to IMRX or SYBX? In the previous week, Immuneering had 3 more articles in the media than Synlogic. MarketBeat recorded 5 mentions for Immuneering and 2 mentions for Synlogic. Synlogic's average media sentiment score of 1.44 beat Immuneering's score of 1.32 indicating that Synlogic is being referred to more favorably in the news media. Company Overall Sentiment Immuneering Positive Synlogic Positive Which has better valuation & earnings, IMRX or SYBX? Immuneering has higher revenue and earnings than Synlogic. Immuneering is trading at a lower price-to-earnings ratio than Synlogic, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmuneering$320K145.07-$53.47M-$2.03-0.64Synlogic$8K1,688.61-$57.28M-$2.51-0.46 Do institutionals & insiders have more ownership in IMRX or SYBX? 67.7% of Immuneering shares are owned by institutional investors. Comparatively, 63.4% of Synlogic shares are owned by institutional investors. 25.0% of Immuneering shares are owned by company insiders. Comparatively, 3.0% of Synlogic shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is IMRX or SYBX more profitable? Immuneering's return on equity of -79.19% beat Synlogic's return on equity.Company Net Margins Return on Equity Return on Assets ImmuneeringN/A -79.19% -69.08% Synlogic N/A -207.84%-114.81% SummaryImmuneering beats Synlogic on 11 of the 17 factors compared between the two stocks. Get Synlogic News Delivered to You Automatically Sign up to receive the latest news and ratings for SYBX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SYBX vs. The Competition Export to ExcelMetricSynlogicPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.51M$6.85B$5.54B$7.93BDividend YieldN/A2.97%5.09%4.22%P/E Ratio-0.287.3222.5518.54Price / Sales1,688.61241.43395.25103.29Price / CashN/A65.8538.1834.62Price / Book0.256.486.764.25Net Income-$57.28M$143.41M$3.22B$248.18M7 Day Performance1.32%2.58%1.37%1.03%1 Month Performance-3.75%5.00%2.77%2.70%1 Year Performance-38.56%-3.72%15.59%4.05% Synlogic Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SYBXSynlogic2.4744 of 5 stars$1.16+1.8%N/A-39.2%$13.57M$8,000.00-0.2880Short Interest ↓Positive NewsGap DownIMRXImmuneering3.7879 of 5 stars$1.38+8.7%$12.50+805.8%-15.7%$49.52M$320,000.00-0.7060Upcoming EarningsShort Interest ↓News CoveragePositive NewsPDSBPDS Biotechnology1.5276 of 5 stars$1.08flat$9.00+733.3%-63.2%$49.03MN/A-0.9320Gap UpSKYESkye Bioscience1.3406 of 5 stars$1.57+9.4%$16.60+957.3%-84.1%$48.63MN/A-2.1811Gap DownGANXGain Therapeutics2.8306 of 5 stars$1.74-3.3%$8.20+371.3%-26.6%$48.35M$50,000.00-1.5820News CoverageICCCImmuCell0.9613 of 5 stars$5.38-2.2%N/A+7.5%$48.33M$26.49M-10.7670Gap DownCUECue Biopharma4.0671 of 5 stars$0.78+2.5%$3.00+284.0%-60.5%$48.29M$9.29M-0.8760Upcoming EarningsVNRXVolitionRx1.7685 of 5 stars$0.48-2.4%$3.33+597.4%-43.7%$48.16M$1.23M-1.3380Analyst ForecastNews CoverageOTLKOutlook Therapeutics1.8378 of 5 stars$1.47+1.4%$10.20+593.9%-81.5%$47.07MN/A-0.2020AVTXAvalo Therapeutics4.0505 of 5 stars$4.41flat$33.00+648.3%-68.5%$47.06M$441,000.000.0040News CoverageCYCCCyclacel Pharmaceuticals3.3001 of 5 stars$0.21-6.6%$11.00+5,110.8%-90.8%$46.88M$74,000.00-0.0214Dividend AnnouncementEx-DividendAnalyst ForecastNews CoverageGap Down Related Companies and Tools Related Companies Immuneering Competitors PDS Biotechnology Competitors Skye Bioscience Competitors Gain Therapeutics Competitors ImmuCell Competitors Cue Biopharma Competitors VolitionRx Competitors Outlook Therapeutics Competitors Avalo Therapeutics Competitors Cyclacel Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SYBX) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredWhat President Trump’s Executive Order 14154 means for your moneyNearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synlogic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Synlogic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SYBX Stock Free SYBX Stock Alerts